Therefore, direct targeting of ONECUT2 may lead to unfavorable side effects, while targeting of ONECUT2-dependent tumor hypoxia could be a more convenient and optimal choice for NEPC patients. This evidence concerns the gene ONECUT2 and neoplasm.